Scotiabank lowered the firm’s price target on Janux Therapeutics (JANX) to $36 from $41 and keeps a Sector Perform rating on the shares. The firm cut its price target on the stock based on the lower probability of success for its Phase 1 trial of JANX007, which the firm believes is “more appropriate” for a Phase 1 cancer drug with limited patient exposure, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Promising Pipeline and Strategic Advancements Justify Buy Rating for Janux Therapeutics Inc
- Positive Buy Rating for Janux Therapeutics Inc. Driven by Promising Clinical Data and Strong Financial Position
- Buy Rating Affirmed for Janux Therapeutics: Promising Clinical Data and Superior Efficacy of Lead Program JANX007
- Janux Therapeutics Inc: Undervalued Growth Potential Amid Recent Stock Pullback
- Janux Therapeutics reports Q1 EPS (38c), consensus (39c)